C-Path Institute’s New Washington Office May Enhance PGx Efforts, Funding Opportunities | GenomeWeb
The Critical Path Institute’s new presence in Washington, DC, may help fuel its pharmacogenomics research, particularly drug-diagnostic co-development partnerships.
 
Earlier this month, the Tucson, Ariz.-based non-profit opened an office in the nation’s capital, which placed it in the midst of Congress, regulatory agencies, research organizations, and biotechnology companies. The new digs will likely help raise the profile of C-Path initiatives, including the institute’s PGx efforts.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.